上海三友医疗器械股份有限公司 独立董事候选人声明与承诺 本人李莫愁，已充分了解并同意由提名人上海三友医疗器械股份有限公司董 事会提名为上海三友医疗器械股份有限公司（以下简称"公司"或"三友医疗"） 第四届董事会独立董事候选人。本人公开声明，本人具备独立董事任职资格，保 证不存在任何影响本人担任上海三友医疗器械股份有限公司独立董事独立性的 关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法规、部门规 章及其他规范性文件，具有 5 年以上法律、经济会计、财务、管理等履行独立董 事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司规章的要求： （一）《中华人民共和国公司法》等关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定； （三）中国证监会《上市公司独立董事管理办法》和上海证券交易所自律监 管规则有关独立董事任职资格和条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去公职或者退 （离）休后担任上市公司、基金管理公司独立董事、独立监事的通知》的规定； （五）中共中央组织部《关于进一步规范党政领导 ...

上海三友医疗器械股份有限公司 （六）中共中央纪委、教育部、监察部《关于加强高等学校反腐倡廉建设的 意见》的相关规定； 独立董事提名人声明与承诺 提名人上海三友医疗器械股份有限公司董事会，现提名程昉为上海三友医疗 器械股份有限公司第四届董事会独立董事候选人，并已充分了解被提名人职业、 学历、职称、详细的工作经历、全部兼职、有无重大失信等不良记录等情况。被 提名人已书面同意出任上海三友医疗器械股份有限公司第四届董事会独立董事 候选人（参见该独立董事候选人声明）。提名人认为，被提名人具备独立董事任 职资格，与上海三友医疗器械股份有限公司之间不存在任何影响其独立性的关系， 具体声明并承诺如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、行政法规、规 章及其他规范性文件，具有 5 年以上法律、经济、会计、财务、管理等履行独立 董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训证明材料。 二、被提名人任职资格符合下列法律、行政法规和部门规章的要求： （一）《中华人民共和国公司法》等关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定； （三）中国证监会 ...

上海三友医疗器械股份有限公司 独立董事候选人声明与承诺 本人顾绍宇，已充分了解并同意由提名人上海三友医疗器械股份有限公司董 事会提名为上海三友医疗器械股份有限公司（以下简称"公司"或"三友医疗"） 第四届董事会独立董事候选人。本人公开声明，本人具备独立董事任职资格，保 证不存在任何影响本人担任上海三友医疗器械股份有限公司独立董事独立性的 关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法规、部门规 章及其他规范性文件，具有 5 年以上法律、经济会计、财务、管理等履行独立董 事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司规章的要求： （一）《中华人民共和国公司法》等关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定； （三）中国证监会《上市公司独立董事管理办法》和上海证券交易所自律监 管规则有关独立董事任职资格和条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去公职或者退 （离）休后担任上市公司、基金管理公司独立董事、独立监事的通知》的规定； （五）中共中央组织部《关于进一步规范党政领导 ...

上海三友医疗器械股份有限公司 关于召开2025年第三次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 证券代码：688085 证券简称：三友医疗 公告编号：2025-045 2025年第三次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 7 月 4 日 14 点 00 分 召开地点：上海市嘉定区嘉定工业区汇荣路 385 号公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 7 月 4 日 至2025 年 7 月 4 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2025年7月4日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 东大会召开 ...

Investment Rating - The report gives a "Buy" rating for the company [1] Core Viewpoints - The company is positioned as an innovative domestic orthopedic enterprise focusing on medical orthopedic implant consumables, with strong market competitiveness in spinal implant consumables and ultrasonic bone knives [4][5] - The company has a clear ownership structure with its three co-founders as actual controllers, and it has been actively expanding into new business areas despite traditional business disruptions from centralized procurement policies [20][21] - The company is expected to see steady growth in traditional implant consumables as the impact of centralized procurement diminishes, with significant sales growth projected for its vertebral body augmentation systems and pouch products [5][7] Summary by Sections Company Overview - The company, established in 2005, specializes in the R&D, production, and sales of medical orthopedic implant consumables, particularly in the spinal segment [15] - The management team has extensive experience in multinational medical device companies, ensuring a strong foundation for innovation and market competitiveness [17] Market Environment - The orthopedic implant market has been affected by centralized procurement policies since 2019, leading to significant price reductions and a phase of industry decline [5][29] - The spinal implant market is expected to recover as centralized procurement impacts wane, with domestic companies gaining market share through improved competitiveness [29][36] Product Development - The company is expanding its product ecosystem with the JAZZ series, which includes spinal consumables, ultrasonic bone knives, and orthopedic robots, creating a strong product barrier [6][7] - The ultrasonic bone knife is a new surgical tool that minimizes soft tissue damage and reduces bleeding risks during surgery, showcasing the company's commitment to innovative medical solutions [45] Financial Projections - Revenue is projected to grow significantly from 599 million yuan in 2025 to 952 million yuan in 2027, with net profit expected to increase from 90 million yuan to 238 million yuan during the same period [7][10] - The company is anticipated to achieve a substantial increase in earnings per share (EPS), reflecting strong growth potential in both domestic and international markets [7][10]

Investment Rating - The report gives a "Buy" rating for the company [1] Core Views - The company is positioned as an innovative domestic orthopedic enterprise driven by medical engineering, focusing on spinal implant consumables and ultrasound bone knife technology, with strong market competitiveness [4][5] - The company has a clear ownership structure with its three co-founders as actual controllers, and it has been actively expanding into new business areas despite traditional business challenges [20][21] - The company is expected to see significant revenue growth in the coming years, driven by domestic and international market expansion in spinal consumables and active devices [7][10] Summary by Sections Company Overview - The company specializes in the research, production, and sales of medical orthopedic implant consumables, particularly in the spinal segment, and has a strong original innovation capability [15] - The management team has extensive experience in multinational medical device companies, ensuring a global perspective in operations [17] Market Dynamics - The orthopedic implant market has been affected by centralized procurement policies, leading to a significant price drop in spinal and trauma implant consumables [5][29] - The company has been increasing its market share in the domestic market despite a challenging environment, with sales of its vertebral body augmentation system and pouch products growing over 50% and 45% respectively in 2024 [5] Product Ecosystem - The company is building a product ecosystem around its JAZZ series, ultrasound bone knife, and orthopedic robots, enhancing its competitive edge [6] - The ultrasound bone knife technology is gaining recognition in the market, with the company actively participating in international exhibitions [6][45] Financial Projections - Revenue is projected to grow from 599 million yuan in 2025 to 952 million yuan in 2027, with net profit expected to increase significantly during the same period [7][10] - The company’s gross margin is expected to improve, reflecting a recovery from the impacts of centralized procurement [10][25] Competitive Landscape - The spinal implant market in China is expected to grow, with domestic companies gaining market share as they replace imported products [36][37] - The company is well-positioned to benefit from the ongoing trend of domestic substitution in the orthopedic implant market [36]

Group 1 - The core viewpoint is that the innovative drug sector is experiencing a significant recovery in stock prices, attracting attention from brokers for research and investment opportunities [2] - The Tianhong Innovative Drug ETF (517380) has seen a net inflow of 3.6 million yuan, with a current scale of 389 million yuan as of May 26 [1] - The Tianhong ETF is the only product that comprehensively covers the innovative drug sector across A-shares and Hong Kong stocks, with a focus on the "Hengsheng Huasheng Hong Kong Innovative Drug Selected 50" index [1] Group 2 - The innovative drug industry is entering a new cycle of value reassessment due to a combination of policy, industry, and performance factors [2] - Longjiang Securities suggests that the previous valuation methods used during the bear market may no longer be applicable, indicating a need for a re-evaluation of the valuation system for innovative drug companies [2] - There has been significant interest from brokers, with nearly 60 companies in the pharmaceutical and biotechnology sector being researched this month, highlighting the sector's attractiveness [2]

Meeting Overview - The shareholder meeting of Shanghai Sanyou Medical Devices Co., Ltd. was held on May 23, 2025, in Shanghai [1] - The meeting was convened by the board of directors and chaired by Mr. Michael Mingyan Liu [1] Attendance and Voting - A total of 32 ordinary shareholders attended the meeting, holding 83,064,616 voting rights, which represents 29.8917% of the total voting rights of the company [1] - The voting results for various proposals showed overwhelming support, with the majority of votes in favor [2][3] Resolutions Passed - The non-cumulative voting proposals were approved with 99.9865% of ordinary shareholders voting in favor [2] - The 2024 Board of Directors Work Report, including the independent directors' annual performance report, was also approved with similar support [2][3] Legal Compliance - The meeting's procedures, including the qualifications of attendees and voting processes, complied with the Company Law and the company's articles of association, ensuring the legality and validity of the voting results [3]

Core Viewpoint - The company has announced its 2025 "Quality Improvement and Efficiency Enhancement" action plan, building on the achievements of the 2024 plan to optimize operations and governance while enhancing shareholder value [1]. Group 1: Business Strategy and Development - The company focuses on deepening its core business in orthopedic medical devices, emphasizing original innovation and increasing R&D investment to enhance competitiveness [1][2]. - In 2024, the company faced a significant decline in net profit, down 88% to 11.47 million yuan, primarily due to the impact of centralized procurement on spinal product sales [1]. - The company increased its R&D investment to 84.29 million yuan, a 29.24% year-on-year increase, representing 18.58% of total revenue, up 4.41 percentage points from the previous year [1]. Group 2: International Expansion - The company aims to expand its international business, leveraging its acquisition of Implanet to enhance brand recognition and market presence in developed countries [3][4]. - The JAZZ Spinal System from Implanet received FDA510(k) certification and began sales in the U.S. by the end of 2024, further enriching the company's international product line [3]. Group 3: Product Innovation and Technology - The company is advancing the development of new materials and intelligent surgical devices, focusing on integrating AI and robotics into orthopedic instruments [4][5]. - The acquisition of Waterwood Tianpeng Medical Technology Co., Ltd. aims to enhance the company's capabilities in ultrasound energy and active devices, promoting strategic synergies [6]. Group 4: Shareholder Returns and Communication - The company maintains a sustainable dividend strategy, planning to distribute a total cash dividend of 1.1671 million yuan and a capital reserve increase of 2 shares for every 10 shares held [7][8]. - The company emphasizes transparent communication with investors, utilizing various channels to ensure timely and accurate information dissemination [9][10]. Group 5: Governance and Compliance - The company adheres to strict governance standards, ensuring a well-defined structure among shareholders, the board, and management to protect shareholder interests [12][13]. - Continuous training and communication with key personnel are implemented to enhance compliance awareness and operational effectiveness [13][14].

证券代码：688085 证券简称：三友医疗 公告编号：2025-042 上海三友医疗器械股份有限公司 2024年年度股东大会决议公告 | 1、出席会议的股东和代理人人数 | 32 | | --- | --- | | 普通股股东人数 | 32 | | 2、出席会议的股东所持有的表决权数量 | 83,064,616 | | 普通股股东所持有表决权数量 | 83,064,616 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 29.8917 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 29.8917 | 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 23 日 （二） 股东大会召开的地点：上海市嘉定区嘉定工业区汇荣路 385 号公司会议 室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： （四） ...